AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26879827 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitolisant 200 mg
Number of subjects: 49
Study 26879827 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitolisant 240 mg
Number of subjects: 49
Study 26879827 — intervention group
Group type: COMPARATOR
Intervention: Pitolisant 120 mg
Number of subjects: 49
Study 26879827 — intervention group
Group type: EXPERIMENTAL
Intervention: SAD study
Number of subjects: 49
Study 26879827 — intervention group
Group type: COMPARATOR
Intervention: TQT study
Number of subjects: 49
Study 26879827 — intervention group
Group type: EXPERIMENTAL
Intervention: SAD study at 240 mg
Number of subjects: 49
Study 26879827 — intervention group
Group type: COMPARATOR
Intervention: TQT study at 120 mg
Number of subjects: 49
Study 25437221 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% saline
Number of subjects: 2300
Study 25437221 — intervention group
Group type: COMPARATOR
Intervention: Plasma-Lyte 148
Number of subjects: 2300
Study 23377597 — intervention group
Group type: EXPERIMENTAL
Intervention: Home healthcare services (HHCS)
Number of subjects: 46
Study 20692570 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical group
Number of subjects: 2
Study 20692570 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond group
Number of subjects: 2
Study 18635463 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol
Number of subjects: 174
Study 18635463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study 15717846 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate
Number of subjects: 100
Study 15717846 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants
Number of subjects: 100
Study 15717846 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate plus Antioxidants
Number of subjects: 100
Study 15717846 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 100
Study 12384852 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone/proguanil (4 tablets per day for 3 days)
Number of subjects: 295
Study 12384852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 295
Study 9972735 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental videotape about pediatric anesthesia
Number of subjects: 85
Study 9972735 — intervention group
Group type: COMPARATOR
Intervention: Control videotape with no medical content
Number of subjects: 85
Study 7487145 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms recombinant human interleukin‐2
Number of subjects: 16
Study 7487145 — intervention group
Group type: COMPARATOR
Intervention: Glucose (negative control)
Number of subjects: 16
Study 1840344 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.07 mg/kg i.v.)
Number of subjects: 63
Study 1840344 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (0.14 mg/kg i.v.)
Number of subjects: 63
Study 1840344 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline, 0.07 ml/kg i.v.)
Number of subjects: 63
Study 7049312 — intervention group
Group type: EXPERIMENTAL
Intervention: surgery plus a single fraction of 500 rad (5 Gy)
Number of subjects: 824
Study 7049312 — intervention group
Group type: EXPERIMENTAL
Intervention: surgery plus 2000 rad (20 Gy) in 10 equal daily fractions
Number of subjects: 824
Study 7049312 — intervention group
Group type: COMPARATOR
Intervention: surgery alone
Number of subjects: 824
Study 31062189 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS) at 2-mA for 20 minutes, 5 days per week for 20 days over the left dorsolateral prefrontal cortex (DLPFC).
Number of subjects: 34
Study 31062189 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (control group).
Number of subjects: 34
Study 28536741 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention targeted at treatment adherence
Number of subjects: 236
Study 28536741 — intervention group
Group type: COMPARATOR
Intervention: Control group (psychotic and bipolar disorders)
Number of subjects: 236
Study 26754343 — intervention group
Group type: EXPERIMENTAL
Intervention: Sienna+® (superparamagnetic iron oxide particles)
Number of subjects: 115
Study 26754343 — intervention group
Group type: COMPARATOR
Intervention: Standard technique (isotopes ± blue dye)
Number of subjects: 115
Study 26754343 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods (Sienna+® and standard technique)
Number of subjects: 115
Study 26754343 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative complications assessment
Number of subjects: 115
Study 24405891 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored interventions to implement the six recommendations for managing depression in the elderly
Number of subjects: 80
Study 24405891 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 80
Study 22546741 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication adherence assessment using the Morisky Medication Adherence Scale
Number of subjects: 302
Study 22546741 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-related attributes, drug regimen characteristics, health status, patient-provider interaction
Number of subjects: 302
Study 22546741 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and self-rated health
Number of subjects: 302
Study 19648157 — intervention group
Group type: EXPERIMENTAL
Intervention: Profound haemodilution (haematocrit 19‐21%)
Number of subjects: 60
Study 19648157 — intervention group
Group type: COMPARATOR
Intervention: Standard haemodilution (haematocrit 24‐26%)
Number of subjects: 60
Study 19648157 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (haematocrit 19‐21% and 24‐26%)
Number of subjects: 60
Study 17284731 — intervention group
Group type: EXPERIMENTAL
Intervention: MUFA + EPA/DHA
Number of subjects: 15
Study 17284731 — intervention group
Group type: EXPERIMENTAL
Intervention: MUFA + ALA
Number of subjects: 15
Study 17284731 — intervention group
Group type: COMPARATOR
Intervention: MUFA
Number of subjects: 15
Study 17284731 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 15
Study 15195212 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 20
Study 15195212 — intervention group
Group type: COMPARATOR
Intervention: Calcium Carbonate
Number of subjects: 20
Study 11274903 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril, 2 mg once daily in the morning
Number of subjects: 18
Study 11274903 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 18
Study 9588097 — intervention group
Group type: EXPERIMENTAL
Intervention: Tensitone (7.5% NaCl in 6% dextran 70, Infusia a.s., CR), administered at a dosage of 4 ml/kg
Number of subjects: 81
Study 9588097 — intervention group
Group type: COMPARATOR
Intervention: Standard volume expanders
Number of subjects: 81
Study 7912576 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine 1%
Number of subjects: 105
Study 7912576 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine 1% with Cyclopentolate 1%
Number of subjects: 105
Study 7912576 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine 10% with Cyclopentolate 1%
Number of subjects: 105
Study 7912576 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthetic cases (all groups)
Number of subjects: 105
Study 7912576 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 105
Study 2712981 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate cold therapy
Number of subjects: 143
Study 2712981 — intervention group
Group type: COMPARATOR
Intervention: Simulated therapy (Control)
Number of subjects: 143
Study 1066150 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal methotrexate (MTX) plus dexamethasone (DMT)
Number of subjects: 32
Study 1066150 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal radioactive chromic phosphate (CROP)
Number of subjects: 32
Study 31274603 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated energy drink (160 mg of caffeine)
Number of subjects: 26
Study 31274603 — intervention group
Group type: COMPARATOR
Intervention: Noncaffeinated energy drink
Number of subjects: 26
Study 30917863 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes medication adherence assessment using the Morisky Medication Adherence Scale (MMAS-8)
Number of subjects: 416
Study 30917863 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 18 to 35 years
Number of subjects: 416
Study 30917863 — intervention group
Group type: EXPERIMENTAL
Intervention: Single marital status
Number of subjects: 416
Study 30917863 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of diabetes-related complications
Number of subjects: 416
Study 30917863 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeling worse
Number of subjects: 416
Study 27993829 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 100 mg once daily
Number of subjects: 594
Study 27993829 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg daily
Number of subjects: 594
Study 27993829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 594
Study 27993829 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 100 mg daily
Number of subjects: 594
Study 27993829 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib (both regimens)
Number of subjects: 594
Study 27993829 — intervention group
Group type: COMPARATOR
Intervention: Filgotinib and Placebo
Number of subjects: 594
Study 27993829 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib
Number of subjects: 594
Study 26112449 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcard intervention (sent once a month for eight months)
Number of subjects: 184
Study 26112449 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcard intervention
Number of subjects: 184
Study 26112449 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 184
Study 24616985 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscope-assisted resection via retroauricular hairline approach (RHA)
Number of subjects: 25
Study 24616985 — intervention group
Group type: COMPARATOR
Intervention: Conventional transcervical approach resection
Number of subjects: 25
Study 21571233 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 114
Study 21571233 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 114
Study 18443343 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone (4 mg)
Number of subjects: 380
Study 18443343 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 380
Study 17213596 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg per day
Number of subjects: 48
Study 17213596 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg per day
Number of subjects: 48
Study 12874677 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (100 micro g administered as an intravenous bolus)
Number of subjects: 11
Study 10743822 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release codeine (50 mg every 12 h at baseline, escalated to 159 mg every 12 h at final assessment)
Number of subjects: 66
Study 10743822 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release codeine
Number of subjects: 66
Study 10743822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 9206057 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (n = 478, Group I)
Number of subjects: 822
Study 9206057 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (n = 344, Group II)
Number of subjects: 822
Study 1393033 — intervention group
Group type: EXPERIMENTAL
Intervention: Anistreplase 30 units intravenously
Number of subjects: 311
Study 1393033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 311
Study 2996028 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH 4‐9 analog (ORG 2766) 40 mg
Number of subjects: 13
Study 2996028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 31088728 — intervention group
Group type: EXPERIMENTAL
Intervention: DM + CKD
Number of subjects: 1046
Study 31088728 — intervention group
Group type: EXPERIMENTAL
Intervention: DM + CVD
Number of subjects: 1046
Study 31088728 — intervention group
Group type: EXPERIMENTAL
Intervention: DM + CVD + CKD
Number of subjects: 1046
Study 30232113 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow heated and humidified nasal oxygen (HFHO) therapy
Number of subjects: 242
Study 30232113 — intervention group
Group type: COMPARATOR
Intervention: Standard oxygen therapy
Number of subjects: 242
Study 27152759 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) infusion at 0.25 μg/kg/hour for 96 hours starting 1 hour after portal venous reperfusion
Number of subjects: 0
Study 27152759 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) infusion
Number of subjects: 0
Study 23841569 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir (IDet)
Number of subjects: 36
Study 23841569 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (IGlar)
Number of subjects: 36
Study 22592665 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg per day increased to 300 mg per day
Number of subjects: 64
Study 22592665 — intervention group
Group type: COMPARATOR
Intervention: Calcium channel blocker (CCB) group with amlodipine increased from 7.5 mg to 10 mg per day
Number of subjects: 64
Study 20348368 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA-FFA (2 g daily for 6 months)
Number of subjects: 55
Study 20348368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 18547853 — intervention group
Group type: EXPERIMENTAL
Intervention: NIOX MINO
Number of subjects: 70
Study 15805751 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-arm casting (n=44)
Number of subjects: 83
Study 15805751 — intervention group
Group type: COMPARATOR
Intervention: Short-arm casting (n=39)
Number of subjects: 83
Study 11818294 — intervention group
Group type: EXPERIMENTAL
Intervention: History of unwanted sexual activity during childhood
Number of subjects: 2676
Study 10599356 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg/day)
Number of subjects: 41
Study 10599356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 7551841 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg once daily
Number of subjects: 296
Study 7551841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 296
Study 1827016 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release isradipine (isradipine SR) 5 mg/day
Number of subjects: 73
Study 1827016 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release isradipine (isradipine SR) 10 mg/day
Number of subjects: 73
Study 6953986 — intervention group
Group type: EXPERIMENTAL
Intervention: Daunorubicin (DNR) 45 mg/sq m
Number of subjects: 0
Study 6953986 — intervention group
Group type: EXPERIMENTAL
Intervention: Daunorubicin (DNR) 30 mg/sq m
Number of subjects: 0
Study 6953986 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin (ADM) 30 mg/sq m
Number of subjects: 0
Study 31479005 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention (9-month curriculum, daily after school)
Number of subjects: 0
Study 31479005 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group (no intervention)
Number of subjects: 0
Study 31479005 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 0
Study 30887570 — intervention group
Group type: EXPERIMENTAL
Intervention: β-D-Mannuronic acid (1000 mg/d, 2 capsules orally for 8 weeks)
Number of subjects: 48
Study 30887570 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of tumor markers (carcinoembryonic antigen and cancer antigen 15-3)
Number of subjects: 48
Study 30887570 — intervention group
Group type: EXPERIMENTAL
Intervention: β-D-Mannuronic acid therapy
Number of subjects: 48
Study 27471798 — intervention group
Group type: EXPERIMENTAL
Intervention: ANA intervention (education and feedback)
Number of subjects: 20
Study 27471798 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus group discussions
Number of subjects: 20
Study 25227774 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 88
Study 25227774 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 88
Study 25227774 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Propofol and Isoflurane
Number of subjects: 88
Study 23845016 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapoxetine 30 mg
Number of subjects: 495
Study 23845016 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapoxetine 60 mg
Number of subjects: 495
Study 23845016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 495
Study 21873264 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg plus daily glucocorticosteroids
Number of subjects: 44
Study 21873264 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus daily glucocorticosteroids
Number of subjects: 44
Study 21873264 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab plus glucocorticosteroids
Number of subjects: 44
Study 20008203 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists (warfarin) for patients with antiphospholipid antibodies and venous thromboembolism
Number of subjects: 0
Study 20008203 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin or warfarin for ischemic stroke
Number of subjects: 0
Study 20008203 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic-dose heparin and aspirin for women with recurrent pregnancy loss
Number of subjects: 0
Study 20008203 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotic therapy in patients with APS-associated thrombocytopenia
Number of subjects: 0
Study 16355282 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral alendronate 1 mg/kg/day
Number of subjects: 18
Study 16355282 — intervention group
Group type: COMPARATOR
Intervention: Intravenous pamidronate 3 mg/kg/4 months
Number of subjects: 18
Study 15104556 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose therapy (1 mg/day oestradiol‐17 beta with 5 or 10 mg/day dydrogesterone)
Number of subjects: 24
Study 15104556 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose therapy (2 mg/day oestradiol‐17 beta with 10 or 20 mg/day dydrogesterone)
Number of subjects: 24
Study 11023656 — intervention group
Group type: EXPERIMENTAL
Intervention: Drawing condition (children asked to draw true and false reminders)
Number of subjects: 0
Study 11023656 — intervention group
Group type: COMPARATOR
Intervention: Question condition (children asked questions about the reminders but not to draw them)
Number of subjects: 0
Study 9731391 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance tests with head extended backwards (additional sensory condition)
Number of subjects: 48
Study 9731391 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance tests with attention-demanding task
Number of subjects: 48
Study 9731391 — intervention group
Group type: COMPARATOR
Intervention: Balance tests without attention-demanding task
Number of subjects: 48
Study 8273241 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg intra-articular morphine
Number of subjects: 50
Study 8273241 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg intra-articular morphine
Number of subjects: 50
Study 8273241 — intervention group
Group type: COMPARATOR
Intervention: Placebo (previous study)
Number of subjects: 50
Study 3304381 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen, 1 mg twice daily
Number of subjects: 8
Study 3304381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31741136 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum albumin level (per SD increase of 0.27 g/dL)
Number of subjects: 12833
Study 31741136 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum albumin level (Q4 vs. Q1)
Number of subjects: 12833
Study 31741136 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomization analysis (per 1 g/dL increase of albumin)
Number of subjects: 12833
Study 30138665 — intervention group
Group type: EXPERIMENTAL
Intervention: Colistin methanesulfonate (CMS) 2 MIU + azidothymidine (AZT) 100 mg
Number of subjects: 7
Study 28235206 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg omega-3 fatty acids from flaxseed oil containing 400 mg α-linolenic acid, twice a day for 12 weeks
Number of subjects: 60
Study 28235206 — intervention group
Group type: COMPARATOR
Intervention: Placebo, twice a day for 12 weeks
Number of subjects: 60
Study 28235206 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg omega-3 fatty acids from flaxseed oil
Number of subjects: 60
Study 26356057 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia (TEA)
Number of subjects: 195
Study 26356057 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin per rectum and opiate analgesic intramuscularly
Number of subjects: 195
Study 26356057 — intervention group
Group type: EXPERIMENTAL
Intervention: TEA in high risk patients
Number of subjects: 195
Study 23924660 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin dosage reduction (n = 249)
Number of subjects: 500
Study 23924660 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin therapy (n = 251)
Number of subjects: 500
Study 23924660 — intervention group
Group type: COMPARATOR
Intervention: No anemia (n = 187)
Number of subjects: 500
Study 23924660 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin therapy (n = 295)
Number of subjects: 500
Study 23924660 — intervention group
Group type: COMPARATOR
Intervention: No erythropoietin therapy (n = 392)
Number of subjects: 500
Study 21918294 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical irritation of the esophagus with acid and capsaicin perfusion
Number of subjects: 0
Study 21918294 — intervention group
Group type: COMPARATOR
Intervention: Placebo perfusions
Number of subjects: 0
Study 18597068 — intervention group
Group type: COMPARATOR
Intervention: 2003 recommended American Diabetes Association diet (ADA)
Number of subjects: 259
Study 18597068 — intervention group
Group type: COMPARATOR
Intervention: Low glycaemic index (LGI) diet
Number of subjects: 259
Study 18597068 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Mediterranean diet (MMD)
Number of subjects: 259